Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Colorectal Neoplasms 2Cardiotoxicity 2Breast Neoplasms 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peripheral Nervous System Diseases 1Leukemia 1Gastrointestinal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Cognitive Dysfunction 1

Interventions

Exercise 6Transcranial Direct Current Stimulation 4Walking 3Memantine 3Tablets 2Standard of Care 2Methods 2Donepezil 2Cognitive Behavioral Therapy 2mazdutide 1lithium sulfate 1lime 1fasudil 1enzalutamide 1blueberry extract 1beta Carotene 1acetaminophen, aspirin, caffeine drug combination 1XENP 1595 1Vitamin E 1Vitamin D 1Ultraviolet Therapy 1Transcranial Magnetic Stimulation 1Time 1Therapeutics 1Tai Ji 1Sugars 1Sodium Chloride 1Sirolimus 1Silymarin 1Riluzole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cognitive Dysfunction × Silymarin × Clear all
NCT05595109 2022-10-26

Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients

Tanta University

Phase 2/3 Unknown
56 enrolled
Breast

Breast Neoplasms, Peripheral Nervous System Diseases, Cognitive Dysfunction, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡